The New Oral MS Drugs: The Challenges in Dislodging Biologics
Executive Summary
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
You may also be interested in...
EU Regulators Reject Merck KGaA's Oral MS Drug Cladribine
Surprise rejection hits German drugmaker hard and casts doubt over FDA approval.
Biogen Idec Taps Exelixis' Scangos To Be New CEO
Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.
Biogen Idec Taps Exelixis' Scangos To Be New CEO
Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.